Ensysce Biosciences (ENSC) Assets Average (2018 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Assets Average of $5.3 million for Q4 2025, down 29.04% year-over-year from $7.5 million in Q4 2024, and up 21.45% quarter-over-quarter from $4.4 million in Q3 2025.
Ensysce Biosciences (ENSC) Assets Average (2018 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Assets Average for 8 consecutive years, with $5.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Assets Average fell 29.04% year-over-year to $5.3 million; the TTM figure through Dec 2025 stood at $5.3 million (down 29.04% YoY), while the FY2025 annual figure was $6.5 million, up 57.12% from the prior year.
- Assets Average advanced to $5.3 million in Q4 2025 per ENSC's latest filing, from $4.4 million in the prior quarter.
- Across five years, Assets Average topped out at $14.4 million in Q1 2022 and bottomed at $1.1 million in Q3 2021.
- Historically, Assets Average has averaged $6.1 million across 5 years, with a median of $5.2 million in 2023.
- Annual changes were most pronounced in 2021 — Assets Average tumbled 94.83% — and 2022, when it jumped 659.57%.
- Ensysce Biosciences' Assets Average stood at $8.7 million in 2021, then declined by 18.94% to $7.1 million in 2022, then slumped by 58.19% to $3.0 million in 2023, then jumped by 152.78% to $7.5 million in 2024, then slipped by 29.04% to $5.3 million in 2025.
- Business Quant data shows ENSC's Assets Average at $5.3 million in Q4 2025, $4.4 million in Q3 2025, and $5.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Ensysce Biosciences | 960,039.34 | -3.35 Mn | - | 5.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.32 Mn |
| Sep 30, 2025 | 4.38 Mn |
| Jun 30, 2025 | 5.09 Mn |
| Mar 31, 2025 | 5.10 Mn |
| Dec 31, 2024 | 7.49 Mn |
| Sep 30, 2024 | 6.09 Mn |
| Jun 30, 2024 | 3.93 Mn |
| Mar 31, 2024 | 3.89 Mn |
| Dec 31, 2023 | 2.96 Mn |
| Sep 30, 2023 | 4.79 Mn |
| Jun 30, 2023 | 5.14 Mn |
| Mar 31, 2023 | 4.90 Mn |
| Dec 31, 2022 | 7.09 Mn |
| Sep 30, 2022 | 8.12 Mn |
| Jun 30, 2022 | 10.16 Mn |
| Mar 31, 2022 | 14.39 Mn |
| Dec 31, 2021 | 8.74 Mn |
| Sep 30, 2021 | 1.07 Mn |
| Jun 30, 2021 | 7.02 Mn |
| Mar 31, 2021 | 6.67 Mn |